Engineered immune cells suppress HIV in early study, hinting at drug-free control

Engineered immune cells kept HIV under control without standard antiretroviral drugs in two early trial participants, a result that points toward a possible functional-cure path but still sits far from routine care.

Researchers at the University of California, San Francisco are adapting CAR-T cell therapy, a cancer treatment that reprograms a patient’s own T cells, to hunt down HIV-infected cells more effectively. In the small first-in-human study, six participants in the relevant cohorts received the modified cells and then stopped their regular HIV medicine under close monitoring. Two of them later maintained undetectable to very low viral loads, one for nearly a year and the other for nearly two years.

The work was presented in Boston at the annual meeting of the American Society of Gene and Cell Therapy, where more than 2,100 pieces of original research were submitted. The study is still in the early phase of development and remains a long way from proving that HIV can be cured or that daily therapy can safely be replaced. Steven Deeks, who led the research, called the response “provocative” and said there is a need for a safe, scalable, one-and-done cure strategy.

The trial, listed on ClinicalTrials.gov as NCT04648046, is an open-label, dose-escalating phase I/IIa study of autologous T cells expressing LVgp120duoCAR molecules. It plans to enroll 18 people at four sites, was still recruiting as of April 9, 2026, and is expected to run until about December 2029. The protocol includes analytic treatment interruption, meaning participants stop standard HIV drugs so investigators can see whether the engineered cells can hold the virus in check.

That is the central promise and the central risk of the approach. Modern antiretroviral therapy has turned HIV from a fast killer into a manageable chronic disease, but it does not remove the latent reservoirs that let the virus rebound when treatment stops. Nearly 40 million people live with HIV worldwide, and lifelong adherence to daily medication remains a barrier for many patients, especially when cost, access, or side effects interfere.

The new strategy builds on earlier milestones in the same UCSF-led program. Nature Medicine reported in 2023 that the first two patients had already received an HIV-targeting CAR-T product, underscoring how experimental the field remains. Company materials tied to the Boston presentation said the two longest responders had been diagnosed and started on HIV treatment relatively quickly, a detail investigators say may matter because early treatment can limit viral damage and reduce the chance for the virus to mutate. For now, the result is best read as a sign that immune-cell engineering may one day help some patients control HIV without lifelong pills, not as proof that the virus has been beaten.